Use of vasopeptidase inhibitors in the treatment of metabolic diseases, nephropathy and advanced glycation end-product associated diseases

US6930103B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Stefan Schafer · Aachen, DE
• Wolfgang Linz · Mainz, DE
• Markus Bleich · Brechen, DE
• Jochen Huber · Mittelbiberach, DE

Key dates

• Filing date: Jun 26, 2003
• Grant date: Aug 16, 2005
• Expiry date: Jul 11, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention describes and claims the use of vasopeptidase inhibitors of formula (I) for the treatment of nephropathy in diabetic or non-diabetic patients, including diabetic or non-diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndome, hypertensive nephrosclerosis, microalbuminuria or end stage renal disease, or insulin resistance or of metabolic diseases associated with advanced glycation end-products, such as diabetic complications, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, myocardial infarction and/or diabetic cardiomyopathy, or atherosclerosis or endothelial dysfunction.